Management of gynaecomastia in patients with prostate cancer: A systematic review

Giuseppe Di Lorenzo, Riccardo Autorino, Sisto Perdonà, Sabino De Placido

Research output: Contribution to journalArticlepeer-review


Patients with prostate cancer are increasingly being offered treatment with non-steroidal antiandrogen monotherapy, which offers potential quality-of-life benefits compared with other treatment. Non-steroidal antiandrogens directly antagonise androgen action in breast tissue, and indirectly increase the oestrogen concentration. Thus, the most troublesome side-effects of monotherapy with these drugs are gynaecomastia and breast pain. Patients younger than 60 years of age, who might not have symptoms of prostate cancer, are probably more concerned about their body image and the development of enlarged breasts than are those older than 60 years. Clinicians who seek a treatment for prostate cancer need information on simple and well-tolerated options for the management of gynaecomastia and breast pain. In this review, management options for gynaecomastia caused by hormonal manipulation in patients with prostate cancer are discussed.

Original languageEnglish
Pages (from-to)972-979
Number of pages8
JournalThe Lancet Oncology
Issue number12
Publication statusPublished - Dec 2005

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Management of gynaecomastia in patients with prostate cancer: A systematic review'. Together they form a unique fingerprint.

Cite this